DELRAY BEACH, Fla., Sept. 8, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that Rogers Communications has chosen to feature PositiveID's iglucose™ mobile health system for diabetes management at the Rogers Wireless Technology Showcase 2011 in major cities throughout Canada during September and October. iglucose, which uses mobile technology to revolutionize the way individuals with diabetes manage their condition, seamlessly communicates blood glucose readings from glucometers to the iglucose diabetes management portal, where the data can be shared in real time with family members, caregivers and healthcare professionals.
According to the Canadian Diabetes Association, more than 9 million Canadians are living with diabetes or pre-diabetes, and diabetes is a contributing factor in the deaths of approximately 41,500 Canadians each year. Healthcare professionals strongly encourage self-monitoring, including keeping journals of blood glucose readings, as the best way for people with diabetes, and their healthcare professionals, to assess the ongoing efficacy of a diabetes management regimen, including medication and patient behavior. However, most people with diabetes do not keep journals. iglucose solves this problem by automatically creating logs and trend reports of blood glucose readings and communicating this information, with the user's consent, to family members and healthcare professionals. Because glucose readings can be shared more frequently, iglucose can play a role in improving care coordination and collaboration as well as aiding in remotely monitoring treatment plans.
In June, PositiveID announced that Rogers Communications is powering machine-to-machine (M2M) wireless data and mobile connectivity management services for PositiveID's iglucose system in Canada. PositiveID is also a member of the Rogers Data Alliance. Rogers commits to offering best in class, innovative, wireless data solutions to address the needs of their customers. The Rogers Data Alliance members are best-in-breed technology organizations that play an essential role in developing and delivering these powerful solutions.
PositiveID has also partnered with MobiCare Technologies Inc. ("MobiCare"), a specialized Canadian healthcare products distributor, to launch iglucose in Canada.
iglucose is currently compatible with Johnson & Johnson's One Touch® Ultra Mini®, One Touch® Ultra® 2, One Touch® Ultra®; Abbott FreeStyle Lite®, FreeStyle Freedom Lite®; Bayer's Contour®, Breeze® 2, Contour® TS; and Nipro/Home Diagnostic's TRUEresult®, TRUEtrack®, TRUEread®, TRUEbalance™. The Company is continually adding to this list of supported glucose meters. iglucose has not been cleared for sale in the U.S. by the United States Food and Drug Administration or in Canada by Health Canada.
The Canadian Diabetes Association estimates that by 2020 diabetes will cost the Canadian healthcare system $16.9 billion a year.
For more information on iglucose, please visit www.iglucose.com.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the ability of iglucose, which uses mobile technology to revolutionize the way individuals with diabetes manage their condition, to seamlessly communicate blood glucose readings from glucometers to the iglucose diabetes management portal, where the data can be shared in real-time with family members, caregivers and health care professionals; the likelihood that because glucose readings can be shared more frequently, iglucose can play a role in improving care coordination and collaboration as well as aiding in remotely monitoring treatment plans; the ability of PositiveID through its relationship with MobiCare to launch iglucose in Canada; the likelihood that iglucose is currently compatible with the aforementioned blood glucose meters and the likelihood that the Company is continually adding to this list of supported glucose meters; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to receive FDA clearance to market iglucose in the U.S. and the ability to receive approval from Health Canada to market iglucose in Canada; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011 and August 15, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
All trademarks are property of their respective owners.